00:52 , Jan 18, 2017 |  BC Week In Review  |  Clinical News

AQS1301: Clinical trial started

Aequus began a Canadian proof-of-concept (POC) trial to evaluate once-weekly transdermal AQS1301 for 4 weeks in 8 healthy male volunteers. Aequus and Corium are partnered to develop AQS1301. Aequus has an exclusive, worldwide license to...
08:00 , Feb 22, 2016 |  BC Week In Review  |  Clinical News

AQS1301: Phase I data

A double-blind, placebo-controlled, Canadian Phase I trial in 12 healthy volunteers showed that once-weekly transdermal AQS1301 was well tolerated with no serious adverse events reported. Aequus and Corium are partnered to develop AQS1301. Aequus has...